Overview

Description

  • Nature
    Synthetic
  • Amino Acid Sequence

    Associated products

    Specifications

    Our Abpromise guarantee covers the use of ab177141 in the following tested applications.

    The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

    • Applications

      Blocking - Blocking peptide for Anti-RUNX1 / AML1 + RUNX3 + RUNX2 antibody [EPR3099] (ab92336)

    • Form
      Liquid
    • Additional notes

      - First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
      - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
      - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
      - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
      - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

    • Concentration information loading...

    Preparation and Storage

    • Stability and Storage

      Shipped at 4°C. Store at -20°C.

    General Info

    • Alternative names
      • Acute myeloid leukemia 1
      • Acute myeloid leukemia 1 protein
      • alpha subunit core binding factor
      • AML 1
      • AML1
      • AML1 EVI 1
      • AML1 EVI 1 fusion protein
      • Aml1 oncogene
      • AMLCR 1
      • AMLCR1
      • CBF alpha 2
      • CBF-alpha-2
      • CBFA 2
      • CBFA2
      • Core binding factor alpha 2 subunit
      • Core binding factor runt domain alpha subunit 2
      • Core-binding factor subunit alpha-2
      • EVI 1
      • EVI1
      • HGNC
      • Oncogene AML 1
      • Oncogene AML-1
      • OTTHUMP00000108696
      • OTTHUMP00000108697
      • OTTHUMP00000108699
      • OTTHUMP00000108700
      • OTTHUMP00000108702
      • PEA2 alpha B
      • PEA2-alpha B
      • PEBP2 alpha B
      • PEBP2-alpha B
      • PEBP2A2
      • PEBP2aB
      • Polyomavirus enhancer binding protein 2 alpha B subunit
      • Polyomavirus enhancer-binding protein 2 alpha B subunit
      • Run1
      • Runt related transcription factor 1
      • Runt-related transcription factor 1
      • RUNX 1
      • Runx1
      • RUNX1_HUMAN
      • SL3 3 enhancer factor 1 alpha B subunit
      • SL3-3 enhancer factor 1 alpha B subunit
      • SL3/AKV core binding factor alpha B subunit
      • SL3/AKV core-binding factor alpha B subunit
      see all
    • Function
      CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits MYST4-dependent transcriptional activation.
    • Tissue specificity
      Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood.
    • Involvement in disease
      Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.
      Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.
      Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.
      Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.
      Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.
      Defects in RUNX1 are the cause of familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]. FPDMM is an autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia.
      Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.
      Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.
    • Sequence similarities
      Contains 1 Runt domain.
    • Domain
      A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes.
    • Post-translational
      modifications
      Phosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with MYST3.
      Methylated.
    • Cellular localization
      Nucleus.
    • Information by UniProt

    References

    ab177141 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab177141.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up